Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin and Warfarin Interaction Study
NCT02340988Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Apr 2015
- Primary completion
- Sep 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of oritavancin in acute bacterial skin and skin structure infections (ABSSSI) (2 arms), sponsored by Melinta Therapeutics. Primary endpoint: Ratio of warfarin PK parameters - AUC and Cmax pre and post oritavancin dose. Started Apr 2015; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02340988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340988.